2013 ACCF/AHA Guideline for the Management of Heart Failure COPYRIGHT
|
|
- Justina Sherman
- 5 years ago
- Views:
Transcription
1 2013 ACCF/AHA Guideline for the Management of Heart Failure by Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E. Casey, Mark H. Drazner, Gregg C. Fonarow, Stephen A. Geraci, Tamara Horwich, James L. Januzzi, Maryl R. Johnson, Edward K. Kasper, Wayne C. Levy, Frederick A. Masoudi, Patrick E. McBride, John J.V. McMurray, Judith E. Mitchell, Pamela N. Peterson, Barbara Riegel, Flora Sam, Lynne W. Stevenson, W.H. Wilson Tang, Emily J. Tsai, and Bruce L. Wilkoff Circulation Volume 128(16):e240-e327 October 15, 2013
2 Applying Classification of Recommendation and Level of Evidence.
3 Recommendations for Biomarkers in HF.
4 From: BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial JAMA. 2009;301(4): doi: /jama Figure Legend: BNP indicates brain natriuretic peptide; LVEF, left ventricular ejection fraction. Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
5 From: BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial JAMA. 2009;301(4): doi: /jama Figure Legend: BNP indicates brain natriuretic peptide. Error bars indicate standard error of the mean. P <.001 for the differences between the treatment groups for both age groups. Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
6 From: BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial JAMA. 2009;301(4): doi: /jama Figure Legend: A, Symptoms expressed as NYHA class. B, N-terminal BNP levels. Boxes indicate interquartile range; horizontal lines, median; error bars, 10th and 90th percentiles. The improvements by both treatment strategies were significant in both age groups (all P <.001). There were no significant differences between the 2 treatment groups by age for symptoms (P =.11 for <75 years vs P =.38 for 75 years) or by N-terminal BNP level (P =.06 vs P =.30). Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
7 From: BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial JAMA. 2009;301(4): doi: /jama Figure Legend: Relationship between New York Heart Association (NYHA) class and N-terminal BNP levels at visits from baseline to month 12 of all patients showing higher N-terminal BNP levels with higher NYHA class (Spearman r = 0.36, P<.001) and a trend to lower N-terminal BNP levels within each NYHA class from baseline to month 12 (NYHA I: Spearman r = 0.34, P =.001; NYHA II: Spearman r = 0.21, P<.001; NYHA III: Spearman r = 0.15, P<.001; NYHA IV: Spearman r = 0.04, P =.69). Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
8 From: BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial JAMA. 2009;301(4): doi: /jama Figure Legend: NT-BNP indicates N-terminal brain natriuretic peptide; CI, confidence interval; HF, heart failure; HR, hazard ratio. Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
9 From: BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial JAMA. 2009;301(4): doi: /jama Figure Legend: The differences between treatment groups were observed only in younger but not older patients. NT-BNP indicates N-terminal brain natriuretic peptide; CI, confidence interval; HF, heart failure; HR, hazard ratio. Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
10 From: BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial JAMA. 2009;301(4): doi: /jama Figure Legend: Subgroup analysis between the age groups was prespecified. Values for body mass index (BMI, calculated as weight in kilograms divided by height in meters squared), N-terminal BNP, and creatinine were subdivided by median values. The size of the data markers represents the number of patients in each group. BNP indicates brain natriuretic peptide; CI, confidence interval; HF, heart failure; HR, hazard ratio. a P <.05 for interaction. b P <.10 for interaction. Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
11 From: B-Type Natriuretic Peptide Guided Heart Failure Therapy: A Meta-analysis Arch Intern Med. 2010;170(6): doi: /archinternmed Figure Legend: Quality of Reporting of Meta-analyses (QUOROM) flow diagram. ANP indicates atrial natriuretic; BNP, B-type natriuretic peptide; CNP, C-type natriuretic peptide; HF, heart failure; RCT, randomized controlled trial. Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
12 From: B-Type Natriuretic Peptide Guided Heart Failure Therapy: A Meta-analysis Arch Intern Med. 2010;170(6): doi: /archinternmed Figure Legend: All-cause mortality meta-analysis of individual trials. Fixed-effects model (χ 2 = 3.75; P =.59). CI indicates confidence interval. Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
13 From: B-Type Natriuretic Peptide Guided Heart Failure Therapy: A Meta-analysis Arch Intern Med. 2010;170(6): doi: /archinternmed Figure Legend: Funnel plot of individual trials (filled circles) contributing to all-cause mortality meta-analysis. RR indicates relative risk. Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
14 From: B-Type Natriuretic Peptide Guided Heart Failure Therapy: A Meta-analysis Arch Intern Med. 2010;170(6): doi: /archinternmed Figure Legend: Fixed-effects models. A, All-cause hospitalization meta-analysis of individual trials (χ 2 = 0.78; P =.68); B, survival free of any hospitalization meta-analysis of individual trials (χ 2 = 0.00; P =.98). CI indicates confidence interval. The size of squares reflects weighting for each study. The diamonds indicate the overall results, with the middle being the RR and the outer tips reflecting the 95% CIs around the result. Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
15 From: B-Type Natriuretic Peptide Guided Heart Failure Therapy: A Meta-analysis Arch Intern Med. 2010;170(6): doi: /archinternmed Figure Legend: Patients having medical treatment adjustment. A, Percentage of patients having doses of medication increased; B, percentage change of patients reaching target dose. ACE indicates angiotensin-converting enzyme; BNP, B-type natriuretic peptide. Date of download: 5/27/2014 Copyright 2014 American Medical Association. All rights reserved.
16 Recommendations for Noninvasive Cardiac Imaging.
17 Recommendations for Invasive Evaluation.
18 Recommendations for Treatment of Stage B HF.
19 Stage C HFrEF: evidence-based, guideline-directed medical therapy.
20 Recommendations for Pharmacological Therapy for Management of Stage C HFrEF.
21 Recommendations for Treatment of HFpEF.
22 Recommendations for Device Therapy for Management of Stage C HF.
23 Indications for CRT therapy algorithm.
24 Recommendations for Inotropic Support, MCS, and Cardiac Transplantation.
25 Stages in the development of HF and recommended therapy by stage.
26 Classification of patients presenting with acutely decompensated heart failure.
27 Recommendations for Therapies in the Hospitalized HF Patient.
28 Recommendations for Hospital Discharge.
29 Pharmacological management of patients with newly discovered AF. AF indicates atrial fibrillation; and HF, heart failure.
30 Pharmacological management of patients with recurrent paroxysmal AF. AF indicates atrial fibrillation.
31 Recommendations for Surgical/Percutaneous/Transcatheter Interventional Treatments of HF.
CONGESTIVE HEART FAILURE
CONGESTIVE HEART FAILURE ACOI IM BOARD REVIEW 2018 MARTIN C. BURKE, DO, FACOI DISCLOSURES I AM PRINCIPAL INVESTIGATOR AND RECEIVE GRANTS FOR HEART FAILURE TRIALS FROM BOSTON SCIENTIFIC, MEDTRONIC AND ST
More informationAUTHOR LISTING OF COMPREHENSIVE RELATIONSHIPS WITH INDUSTRY AND OTHERS
2013 ACCF/AHA Guideline for the Management of Heart Failure ONLINE AUTHOR LISTING OF COMPREHENSIVE RELATIONSHIPS WITH INDUSTRY AND OTHERS (May 2013) Member Employment Consultant Speaker s Bureau Personal
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest
More informationClinical Pearls Heart Failure Cardiology/New Drugs
Clinical Pearls Heart Failure Cardiology/New Drugs Friday, September 9 th, 2016 Heidi Burres, PharmD, BCACP MTM Pharmacist Fairview Pharmacy Services Thank You to XYZ Event Sponsor(s): Wi-fi Information:
More informationTo download handouts for today s presentation, click the three paper icon at the top right of your screen.
To download handouts for today s presentation, click the three paper icon at the top right of your screen. Get With The Guidelines Heart Failure PMT Spring Update September 9, 2013 Clyde W. Yancy, MD,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Entresto) Reference Number: CP.PMN.67 Effective Date: 11.01.15 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Corlanor) Reference Number: CP.PMN.70 Effective Date: 11.01.15 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationWhat s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA
What s new in the 2017 heart failure guidelines Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA Key points to remember 2017 guidelines recommend using natriuretic peptides as biomarkers to screen for heart
More informationThe Purpose of the Chronic Heart Failure Model Practice
The Purpose of the Chronic Heart Failure Model Practice The 2018 PACE Chronic Heart Failure Model Practice provides relevant diagnostic and treatment recommendations to PACE primary care providers (PCPs).
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationCirculation. 2013;128:e240-e327; originally published online June 5, 2013; doi: /CIR.0b013e31829e8776
2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Clyde W. Yancy, Mariell
More information2013 ACCF/AHA Guideline for the Management of Heart Failure
ACCF/AHA PRACTICE GUIDELINE 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationADULT CARDIOVASCULAR CLINICAL PRACTICE GUIDELINES
ADULT CARDIOVASCULAR CLINICAL PRACTICE GUIDELINES Risk Intervention Lifestyle Interventions Hypertension Cholesterol Management Recommendations 1. Smoking cessation 2. Maintain ideal weight or weight reduction
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationMihai Gheorghiade MD
Mihai Gheorghiade MD Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois On behalf of: Stephen J Greene MD; Javed Butler MD MPH MBA; Gerasimos Filippatos
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationHeart Failure 2014: It's No Longer about Failure
Ohio-ACC Spring Summit 2014: 7th Annual CCA Cardiovascular Update & 51st Annual Carl J. Wiggers Memorial Lecture Heart Failure 2014: It's No Longer about Failure Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationREVIEW ARTICLE. Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2
Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2 1 University of Missouri School of Medicine, Columbia, MO 2 Division of Cardiovascular Medicine, Department
More informationSUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics
Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationHow might biomarkers and other strategies help establish adequacy of care?
How might biomarkers and other strategies help establish adequacy of care? James L. Januzzi, Jr, MD, FACC, FESC Hutter Family Professor of Medicine, Harvard Medical School Cardiology Division, Massachusetts
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationRate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications.
Article ID: WMC004618 ISSN 2046-1690 Rate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications. Peer review status: No Corresponding
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationDiagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham
Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Chronic heart failure
More informationHEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida
HEART FAILURE IN WOMEN Marian Limacher, MD Division of Cardiovascular Medicine University of Florida Outline Epidemiology Clinical Overview Why HF is such a challenge State of the Field Heart Failure Adjudication
More informationAssessment and Diagnosis of Heart Failure
Assessment and Diagnosis of Heart Failure Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection of blood and is characterized
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationCharacterization of heart failure patients with mid-range left ventricular ejection fraction a report from the CHART-2 Study
European Journal of Heart Failure (217) 19, 1258 1269 doi:1.12/ejhf.87 RESEARCH ARTICLE Characterization of heart failure patients with mid-range left ventricular ejection fraction a report from the CHART-2
More informationNew Advances in the Diagnosis and Management of Acute and Chronic Heart Failure
New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure Deborah Budge, MD Intermountain Healthcare Heart Failure Cardiologist Objectives: State the updates from the ACC 2013 HF
More informationBiomarker-guided HF: What have we learned (so far)?
Biomarker-guided HF: What have we learned (so far)? James L. Januzzi, Jr, MD, FACC, FESC Associate Professor of Medicine Harvard Medical School Director, Cardiac ICU Massachusetts General Hospital DECLARATION
More informationClinical Investigations
Clinical Investigations Predictors of 30-Day Readmission in Patients Hospitalized With Decompensated Heart Failure Address for correspondence: Gian M. Novaro, MD, Department of Cardiology, Cleveland Clinic
More informationSCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA
Journal Club 19 Marzo 2010 SCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA Alessandro Giordano Prevalence of heart failure by sex and age (NHANES:1999-2004) Circulation 2007 Incidence of heart failure by age
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationCase (Coding Nightmare) Current Dilemmas in Heart Failure : Closing the Gap between Clinical Care and Coding. Current Dilemmas in Heart Failure :
Current Dilemmas in Heart Failure : Closing the Gap between Clinical Care and Coding Interim Vice Chair for Clinical Affairs Department of Medicine, University of Florida 1 2 Case (Coding Nightmare) 69
More informationACCF/AHA Practice Guideline
ACCF/AHA Practice Guideline 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationHeart failure (HF) is a complex clinical syndrome that results in the. impairment of the heart s ability to fill or to pump out blood.
Introduction: Heart failure (HF) is a complex clinical syndrome that results in the impairment of the heart s ability to fill or to pump out blood. As of 2013, an estimated 5.8 million people in the United
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
ACC/AHA/HFSA FOCUSED UPDATE 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION SACUBITRIL/VALSARTAN (Entresto Novartis Pharmaceuticals) Indication: Heart Failure With Reduced Ejection Fraction Recommendation: The Canadian
More informationAngiotensin Neprilysin Inhibition in Acute Decompensated Heart Failure
Original Article Angiotensin Neprilysin Inhibition in Acute Decompensated Heart Failure Eric J. Velazquez, M.D., David A. Morrow, M.D., M.P.H., Adam D. DeVore, M.D., M.H.S., Carol I. Duffy, D.O., Andrew
More informationStatinsshould be in the water supply. Lipid Drug Therapy: Use in Special Populations. Objectives. TSHP 2014 Annual Seminar 1
Lipid Drug Therapy: Use in Special Populations Mark C. Granberry, Pharm.D. Professor Texas A&M Rangel College of Pharmacy Objectives Discuss background for recommendations from the recent AHA/ACC Lipid
More informationHeart Failure Management Policy and Procedure Phase 1
1301 Punchbowl Street, Harkness Suite 225 Honolulu, Hawaii 96813 Phone (808) 691-7220 Fax: (808) 691-4099 www.queenscipn.org Policy and Procedure Phase 1 Policy Number: Effective Date: Revised: Approved
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationCitation. What is New in the 2013 ACC/AHA HF Guideline. Dimensions in Heart and Vascular Care Penn State Heart and Vascular Institute
What is New in the 2013 ACC/AHA HF Guideline Dimensions in Heart and Vascular Care Penn State Heart and Vascular nstitute Friday October 18, 2013 Barry S. Clemson, MD Associate Professor of Medicine Penn
More informationThe Role of Exercise in Management of Patients with Heart Failure
The Role of Exercise in Management of Patients with Heart Failure Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Leadership Council and Section Director,
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationHeart Failure Update. Bibiana Cujec MD May 2015
Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationTỐI ƯU HOÁ ĐIỀU TRỊ SUY TIM MẠN PGS. TS. CHÂU NGỌC HOA ĐHYD TPHCM
TỐI ƯU HOÁ ĐIỀU TRỊ SUY TIM MẠN PGS. TS. CHÂU NGỌC HOA ĐHYD TPHCM Signed by HFA / ESC/ HFSA/ ACC/ AHA Downloaded from http://circ.ahajournals.org/ at Amgen, Inc-- on May 20, 2016 3 In the year 2016, by
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationn Kristensen, S. L., Jhund, P. S., Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., Komajda, M., Cleland, J. G.F., Carson, P. E., and McMurray, J. J.V. (2015) Relative importance of history of heart
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Probing prognosis in heart failure Daniel R. Wagner CHL/INCCI/CRP-Santé Luxembourg Disclosures Grants: Cordis, Boston Scientific, Medtronic, Sorin, Hexacath, Abbott,
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 10/12/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program October 12, 2017 Goal statement To review recently-approved therapies
More informationHighlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France
Highlight Session 2014 Heart failure and cardiomyopathies Michel KOMAJDA Paris France # esccongress www.escardio.org/esc2014 HEART FAILURE AND CARDIOMYOPATHIES TOPIC 1 Drug Therapy TOPIC 2 Device Therapy
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationConflict of Interest Statement. Pharmacy Technician Objectives. Pharmacist Objectives
Updates to Heart Failure Guidelines: Are you ready to SHIFT into a new PARADIGM? Conflict of Interest Statement I have no actual or potential conflict of interest in relation to this activity Denise M
More informationCRT Vs RV Pacing Benefits
CRT-P & CRT-D Indications According to Guidelines are Guidelines Fully Adopted? Salama H. Omar M.D. Prof. Critical Care Medicine, Cairo University CRT Vs RV Pacing Benefits 1 Benefit of Upgrade CTR-P &
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationNew in Heart Failure SGK autumn session 2012
New in Heart Failure SGK autumn session 2012 Roger Hullin Cardiology Department of Internal Medicine Centre Universitaire Hospitaler Vaudois University of Lausanne ESC Heart Failure Guidelines 2012 Classes
More informationBiomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed
Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego
More informationNT-proBNP: Evidence-based application in primary care
NT-proBNP: Evidence-based application in primary care Associate Professor Rob Doughty The University of Auckland, Auckland City Hospital, Auckland Heart Group NT-proBNP: Evidence in Primary Care The problem
More informationRationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients
Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Javed Butler, MD, MPH, MBA Patrick H. Lehan Professor of Medicine Professor of Physiology Chairman,
More informationHeart Failure Therapies State of the Art 2017
Heart Failure Therapies State of the Art 2017 Andrew J. Sauer, MD Assistant Professor Director, Center for Heart Failure Medical Director, Heart Transplantation UNOS Primary Transplant Physician asauer@kumc.edu
More informationA Guide to Proper Utilization of Biomarkers
A Guide to Proper Utilization of Biomarkers DR. ABEER BAKHSH CONSULTANT CARDIOLOGIST, ADVANCE HEART FAILURE KING FAHD ARMED FORCES HOSPITAL JEDDAH, SAUDI ARABIA Objective: Mechanism of myocardial injury
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationAmbarish Pandey, MD UT Southwestern Medical Center Dallas,
Hospital Performance Based on 30-Day Risk Standardized Mortality and Long-Term Survival after Heart Failure Hospitalization An Analysis of the GWTG-HF Registry Ambarish Pandey, MD UT Southwestern Medical
More informationHeart failure (HF) is a clinical syndrome with enormous relevance given its constantly. Benefits of early treatment with
A low percentage of patients achieve optimal β-blocker doses and optimal heart rate values with β-blocker administration. Ivabradine has been recognized not only for providing a prognostic benefit, but
More informationThe Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)
The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) 22 nd Annual Heart Failure 2018 an Update on Therapy April 21, 2018 Los Angeles, CA Barry Greenberg, M.D. Distinguished
More informationHow atrial fibrillation should be treated in the heart failure patient?
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 13/15 Ottobre 2016 How atrial fibrillation should be treated in the heart failure patient? Matteo Anselmino Dipartimento Scienze
More informationSGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016
SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016 Matthias Nägele, MD University Hospital Zurich Disclosures I have nothing to disclose. The new
More informationTuesday October 18, :00pm 2:00pm Central Presenter: Clyde W. Yancy, MD, MSc
Tuesday October 18, 2016 1:00pm 2:00pm Central Presenter: Clyde W. Yancy, MD, MSc Amgen Cardiovascular proudly sponsors Heart Science Amplified: An Online Speaker Series and Get With The Guidelines -Heart
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More information